Q2 Highlights
Q2 revenue was $1,168 million, up 5% underlying and 2% on a reported basis, with -9% currency headwind partially offset by a 6% benefit from acquisitions
Advanced Wound Care improvement continues, with revenue up 12%
Emerging Markets consistently producing double-digit growth
Strong global Knee Implant performance delivers revenue growth of 7%
H1 Highlights
H1 revenue was $2,272 million, up 4% underlying and 2% on a reported basis, with -9% currency headwind partially offset by 7% benefit from acquisitions
H1 trading profit was $512 million, up 6% underlying
Trading profit margin up 70bps at 22.5%
H1 trading profit to cash conversion ratio improved to 75% (H1 2014: 53%)
EPSA 39.1¢, up 3%
Interim Dividend of 11.8¢ per share (2014: 11.0¢)
